(2R,3R)-3-(trityl-amino)-pentan-2-ol

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: (2R,3R)-3-(trityl-amino)-pentan-2-ol
• 英文别名: (2R,3R)-3-(tritylamino)pentan-2-ol
• 化学式: C₂₄H₂₇NO
• 分子量: 345.484
• InChiKey: KZXJWVRCUAGBBS-AUSIDOKSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.73
• 重原子数：
  26.0
• 可旋转键数：
  7.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  32.26
• 氢给体数：
  2.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  (2S,3R)-3-(trityl-amino)-pentan-2-ol 、 (2R,3R)-3-(trityl-amino)-pentan-2-ol 在 草酰氯 、 二甲基亚砜 、 N-乙基哌啶 作用下， 以 二氯甲烷 为溶剂， 反应 21.0h， 以100%的产率得到(3R)-3-(trityl-amino)-pentan-2-one
  参考文献：
  名称：

  [EN] NEW PURINE DERIVATIVES
  [FR] NOUVEAUX DERIVES PURIQUES

  摘要：

  公开号：

  WO2004016612A3
• 作为产物：
  描述：

  三苯基氯甲烷 在 草酰氯 、 copper(I) bromide dimethylsulfide complex 、 二甲基亚砜 、 N,N-二异丙基乙胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 85.0h， 生成 (2S,3R)-3-(trityl-amino)-pentan-2-ol 、 (2R,3R)-3-(trityl-amino)-pentan-2-ol
  参考文献：
  名称：

  Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors

  摘要：

  The cyclin-dependent kinase (CDK) inhibitor seliciclib (1, CYC202) is in phase II clinical development for the treatment of cancer. Here we describe the synthesis of novel purines with greater solubility, lower metabolic clearance, and enhanced potency versus CDKs. These compounds exhibit novel selectivity profiles versus CDK isoforms. Compound alpha SbR-21 inhibits CDK2/cyclin E with IC(50) = 30 nM, CDK7-cyclin H with IC(50) = 1.3 mu M, and CDK9-cyclinT with IC(50) = 0.11 mu M; it (CCT68127) inhibits growth of HCT116 colon cancer cells in vitro with GI(50) = 0.7 mu M; and shows antitumour activity when dosed p.o. at 50 mg/kg to mice bearing HCT116 solid human tumour xenografts. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.08.051

文献信息

• [EN] PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS<br/>[FR] NOUVEAUX DERIVES DE PURINE
  申请人：CYCLACEL LTD

  公开号：WO2004016613A3

  公开（公告）日：2004-04-08
• [EN] NEW PURINE DERIVATIVES<br/>[FR] NOUVEAUX DERIVES PURIQUES
  申请人：CYCLACEL LTD

  公开号：WO2004016612A3

  公开（公告）日：2004-07-01
• Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors
  作者：Stuart C. Wilson、Butrus Atrash、Clare Barlow、Susan Eccles、Peter M. Fischer、Angela Hayes、Lloyd Kelland、Wayne Jackson、Michael Jarman、Amin Mirza、Javier Moreno、Bernard P. Nutley、Florence I. Raynaud、Peter Sheldrake、Mike Walton、Robert Westwood、Steven Whittaker、Paul Workman、Edward McDonald

  DOI：10.1016/j.bmc.2011.08.051

  日期：2011.11

  The cyclin-dependent kinase (CDK) inhibitor seliciclib (1, CYC202) is in phase II clinical development for the treatment of cancer. Here we describe the synthesis of novel purines with greater solubility, lower metabolic clearance, and enhanced potency versus CDKs. These compounds exhibit novel selectivity profiles versus CDK isoforms. Compound alpha SbR-21 inhibits CDK2/cyclin E with IC(50) = 30 nM, CDK7-cyclin H with IC(50) = 1.3 mu M, and CDK9-cyclinT with IC(50) = 0.11 mu M; it (CCT68127) inhibits growth of HCT116 colon cancer cells in vitro with GI(50) = 0.7 mu M; and shows antitumour activity when dosed p.o. at 50 mg/kg to mice bearing HCT116 solid human tumour xenografts. (C) 2011 Elsevier Ltd. All rights reserved.